GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » YoY EBITDA Growth

EQL Pharma AB (FRA:7JK) YoY EBITDA Growth : 38.89% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is EQL Pharma AB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. EQL Pharma AB's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 38.89%.

EQL Pharma AB's EBITDA per Share for the three months ended in Mar. 2024 was €0.03.


EQL Pharma AB YoY EBITDA Growth Historical Data

The historical data trend for EQL Pharma AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB YoY EBITDA Growth Chart

EQL Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 109.09 69.57 305.13 -21.52 -17.74

EQL Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.00 8.00 -48.65 -38.30 38.89

EQL Pharma AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

EQL Pharma AB's YoY EBITDA Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (A: Mar. 2024 )
=(EBITDA per Share (A: Mar. 2024 )-EBITDA per Share (A: Mar. 2023 ))/ | EBITDA per Share (A: Mar. 2023 ) |
=(0.102-0.124)/ | 0.124 |
=-17.74 %

EQL Pharma AB's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(0.025-0.018)/ | 0.018 |
=38.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EQL Pharma AB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of EQL Pharma AB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


EQL Pharma AB (FRA:7JK) Business Description

Traded in Other Exchanges
Address
Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB (FRA:7JK) Headlines

No Headlines